Prometheus Research appoints vp of sales
Prometheus Research, a US provider of database software for biomedical researchers and industry, has named Peter Harker as its new vice president of sales.
Harker takes responsibility for developing and managing sales for the company's Research Informatics biomedical software services and new HTSQL database software for industry.
Prior to joining Prometheus, Harker held a variety of sales roles, most recently as managing director for BondDesk, a provider of software and services for fixed income trading.
You may also like
Digital
![TXP secures £1.5m MHRA contract for cloud architecture and cyber security services]()
TXP secures £1.5m MHRA contract for cloud architecture and cyber security services
The deal extends TXP's existing MHRA partnership, supporting the regulatory agency's digital modernisation through infrastructure development and knowledge transfer as TXP expands its UK public sector footprint
Digital
![Camgenium launches pre-certified Foundation Platform for connected medical device development]()
Camgenium launches pre-certified Foundation Platform for connected medical device development
The infrastructure combines IEC 62304-compliant firmware, ISO 27001 cloud hosting and automated regulatory reporting, letting OEM teams focus engineering effort on clinical differentiation rather than compliance build-out
Finance
![Aplagon closes €4.8m round to advance first-in-class antithrombotic APAC into Phase II AVF trial]()
Aplagon closes €4.8m round to advance first-in-class antithrombotic APAC into Phase II AVF trial
The financing supports a European CTA filing with the EMA for arteriovenous fistula maturation failure in end-stage kidney disease, expanding APAC's clinical programme across thrombo-inflammatory indications
Digital
![ZoBio launches integrated DEL hit discovery service for challenging drug targets]()
ZoBio launches integrated DEL hit discovery service for challenging drug targets
The new library-agnostic platform combines DEL screening with X-ray crystallography, quantitative biophysics and off-DNA validation, delivering structurally characterised, progressible starting points beyond conventional hit identification
Manufacturing
![AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn]()
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn